CD8A and infection: This vaccine would elicit virus-neutralizing antibodies to prevent infection and would generate type 1 cellular immunity, including antigen-specific Th1 CD4+ T-cells and CD8+ T-cells that recognize conserved viral antigens, eliminate infected cells, and prevent reinfection.